关注
Laïla-Aïcha Hanafi
Laïla-Aïcha Hanafi
Caprion Biosciences
在 caprion.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
CJ Turtle, LA Hanafi, C Berger, TA Gooley, S Cherian, M Hudecek, ...
The Journal of clinical investigation 126 (6), 2123-2138, 2016
21362016
Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells
J Gust, KA Hay, LA Hanafi, D Li, D Myerson, LF Gonzalez-Cuyar, C Yeung, ...
Cancer discovery 7 (12), 1404-1419, 2017
12002017
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells
CJ Turtle, LA Hanafi, C Berger, M Hudecek, B Pender, E Robinson, ...
Science translational medicine 8 (355), 355ra116-355ra116, 2016
10512016
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
KA Hay, LA Hanafi, D Li, J Gust, WC Liles, MM Wurfel, JA López, J Chen, ...
Blood, The Journal of the American Society of Hematology 130 (21), 2295-2306, 2017
9782017
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
R Gardner, D Wu, S Cherian, M Fang, LA Hanafi, O Finney, H Smithers, ...
Blood, The Journal of the American Society of Hematology 127 (20), 2406-2410, 2016
7582016
Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib
CJ Turtle, KA Hay, LA Hanafi, D Li, S Cherian, X Chen, B Wood, ...
Journal of Clinical Oncology 35 (26), 3010-3020, 2017
6942017
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
GG Gornalusse, RK Hirata, SE Funk, L Riolobos, VS Lopes, G Manske, ...
Nature biotechnology 35 (8), 765-772, 2017
5282017
Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives
J Godin-Ethier, LA Hanafi, CA Piccirillo, R Lapointe
Clinical cancer research 17 (22), 6985-6991, 2011
4362011
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
A Sheih, V Voillet, LA Hanafi, HA DeBerg, M Yajima, R Hawkins, V Gersuk, ...
Nature communications 11 (1), 219, 2020
1982020
A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells
N Pallet, I Sirois, C Bell, LA Hanafi, K Hamelin, M Dieudé, C Rondeau, ...
Proteomics 13 (7), 1108-1120, 2013
1062013
Anti-CD19 chimeric antigen receptor-modified T Cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion …
CJ Turtle, C Berger, D Sommermeyer, LA Hanafi, B Pender, EM Robinson, ...
Blood 126 (23), 184, 2015
842015
Graft-derived reconstitution of mucosal-associated invariant T cells after allogeneic hematopoietic cell transplantation
A Bhattacharyya, LA Hanafi, A Sheih, JL Golob, S Srinivasan, MJ Boeckh, ...
Biology of Blood and Marrow Transplantation 24 (2), 242-251, 2018
792018
Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance
J Godin-Ethier, S Pelletier, LA Hanafi, PO Gannon, MA Forget, JP Routy, ...
The Journal of Immunology 183 (12), 7752-7760, 2009
622009
Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B …
CJ Turtle, LA Hanafi, C Berger, D Sommermeyer, B Pender, EM Robinson, ...
Blood 126 (23), 3773, 2015
582015
IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive
J Godin-Ethier, LA Hanafi, JB Duvignaud, D Leclerc, R Lapointe
Molecular immunology 49 (1-2), 253-259, 2011
392011
Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes
LA Hanafi, M Bolduc, MÈL Gagné, F Dufour, Y Langelier, MR Boulassel, ...
Vaccine 28 (34), 5617-5626, 2010
322010
Fludarabine downregulates indoleamine 2, 3-dioxygenase in tumors via a proteasome-mediated degradation mechanism
LA Hanafi, D Gauchat, J Godin-Ethier, D Possamai, JB Duvignaud, ...
PLoS One 9 (6), e99211, 2014
312014
Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells.
CJ Turtle, LA Hanafi, C Berger, T Gooley, C Chaney, S Cherian, L Soma, ...
Journal of Clinical Oncology 34 (15_suppl), 102-102, 2016
272016
Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses
G Sarikonda, M Mathieu, M Natalia, A Pahuja, Q Xue, PL Pierog, ...
Cytometry Part B: Clinical Cytometry 100 (1), 79-91, 2021
242021
Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.
CJ Turtle, C Berger, D Sommermeyer, T Budiarto, LA Hanafi, K Melville, ...
Journal of Clinical Oncology 33 (15_suppl), 3006-3006, 2015
232015
系统目前无法执行此操作,请稍后再试。
文章 1–20